Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Mood Disorders | Research article

Disturbances in branched-chain amino acid profile and poor daily functioning in mildly depressed chronic obstructive pulmonary disease patients

Authors: Marisa R. Pinson, Nicolaas E. P. Deutz, Rajesh Harrykissoon, Anthony J. Zachria, Mariëlle P. K. J. Engelen

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

Depression is one of the most common and untreated comorbidities in chronic obstructive pulmonary disease (COPD), and is associated with poor health outcomes (e.g. increased hospitalization/exacerbation rates). Although metabolic disturbances have been suggested in depressed non-diseased conditions, comprehensive metabolic phenotyping has never been conducted in those with COPD. We examined whether depressed COPD patients have certain clinical/functional features and exhibit a specific amino acid phenotype which may guide the development of targeted (nutritional) therapies.

Methods

Seventy-eight outpatients with moderate to severe COPD (GOLD II–IV) were stratified based on presence of depression using a validated questionnaire. Lung function, disease history, habitual physical activity and protein intake, body composition, cognitive and physical performance, and quality of life were measured. Comprehensive metabolic flux analysis was conducted by pulse stable amino acid isotope administration. We obtained blood samples to measure postabsorptive kinetics (production and clearance rates) and plasma concentrations of amino acids by LC–MS/MS. Data are expressed as mean [95% CI]. Stats were done by graphpad Prism 9.1.0. ɑ < 0.05.

Results

The COPD depressed (CD, n = 27) patients on average had mild depression, were obese (BMI: 31.7 [28.4, 34.9] kg/m2), and were characterized by shorter 6-min walk distance (P = 0.055), physical inactivity (P = 0.03), and poor quality of life (P = 0.01) compared to the non-depressed COPD (CN, n = 51) group. Lung function, disease history, body composition, cognitive performance, and daily protein intake were not different between the groups. In the CD group, plasma branched chain amino acid concentration (BCAA) was lower (P = 0.02), whereas leucine (P = 0.01) and phenylalanine (P = 0.003) clearance rates were higher. Reduced values were found for tyrosine plasma concentration (P = 0.005) even after adjustment for the large neutral amino acid concentration (= sum BCAA, tyrosine, phenylalanine and tryptophan) as a marker of dopamine synthesis (P = 0.048).

Conclusion

Mild depression in COPD is associated with poor daily performance and quality of life, and a set of metabolic changes in depressed COPD that include perturbation of large neutral amino acids, specifically the BCAAs.
Trial registration clinicaltrials.gov: NCT01787682, 11 February 2013—Retrospectively registered; NCT02770092, 12 May 2016—Retrospectively registered; NCT02780219, 23 May 2016—Retrospectively registered; NCT03796455, 8 January 2019—Retrospectively registered.
Appendix
Available only for authorised users
Literature
1.
go back to reference Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4 Suppl):43s–56s.PubMedCrossRef Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4 Suppl):43s–56s.PubMedCrossRef
2.
go back to reference Lacasse Y, Rousseau L, Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. J Cardpulm Rehabil. 2001;21(2):80–6.CrossRef Lacasse Y, Rousseau L, Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. J Cardpulm Rehabil. 2001;21(2):80–6.CrossRef
3.
go back to reference Lewis KE, Annandale JA, Sykes RN, Hurlin C, Owen C, Harrison NK. Prevalence of anxiety and depression in patients with severe COPD: similar high levels with and without LTOT. COPD. 2007;4(4):305–12.PubMedCrossRef Lewis KE, Annandale JA, Sykes RN, Hurlin C, Owen C, Harrison NK. Prevalence of anxiety and depression in patients with severe COPD: similar high levels with and without LTOT. COPD. 2007;4(4):305–12.PubMedCrossRef
4.
go back to reference Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31(1):58–69.CrossRef Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31(1):58–69.CrossRef
5.
go back to reference Vanfleteren LEGW, Spruit MA, Groenen M, Gaffron S, van Empel VPM, Bruijnzeel PLB, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–35.PubMedCrossRef Vanfleteren LEGW, Spruit MA, Groenen M, Gaffron S, van Empel VPM, Bruijnzeel PLB, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–35.PubMedCrossRef
6.
go back to reference Yohannes AM, Baldwin RC, Connolly MJ. Mood disorders in elderly patients with chronic obstructive pulmonary disease. Rev Clin Gerontol. 2000;10(2):193–202.CrossRef Yohannes AM, Baldwin RC, Connolly MJ. Mood disorders in elderly patients with chronic obstructive pulmonary disease. Rev Clin Gerontol. 2000;10(2):193–202.CrossRef
8.
go back to reference Dalal AA, Shah M, Lunacsek O, Hanania NA. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD J Chronic Obstr Pulm Disease. 2011;8(4):293–9.CrossRef Dalal AA, Shah M, Lunacsek O, Hanania NA. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD J Chronic Obstr Pulm Disease. 2011;8(4):293–9.CrossRef
9.
go back to reference Hanania NA, Mullerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183(5):604–11.PubMedCrossRef Hanania NA, Mullerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183(5):604–11.PubMedCrossRef
10.
go back to reference Ng T-P, Niti M, Tan W-C, Cao Z, Ong K-C, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167(1):60–7.PubMedCrossRef Ng T-P, Niti M, Tan W-C, Cao Z, Ong K-C, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167(1):60–7.PubMedCrossRef
11.
go back to reference Pooler A, Beech R. Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. Int J Chronic Obstr Pulm Disease. 2014;9:315–30.CrossRef Pooler A, Beech R. Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. Int J Chronic Obstr Pulm Disease. 2014;9:315–30.CrossRef
12.
go back to reference Dahlén I, Janson C. Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest. 2002;122(5):1633–7.PubMedCrossRef Dahlén I, Janson C. Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest. 2002;122(5):1633–7.PubMedCrossRef
13.
go back to reference Catalfo G, Crea L, Lo Castro T, Magnano San Lio F, Minutolo G, Siscaro G, et al. Depression, body mass index, and chronic obstructive pulmonary disease—a holistic approach. Int J Chronic Obstr Pulm Disease. 2016;11:239–49. Catalfo G, Crea L, Lo Castro T, Magnano San Lio F, Minutolo G, Siscaro G, et al. Depression, body mass index, and chronic obstructive pulmonary disease—a holistic approach. Int J Chronic Obstr Pulm Disease. 2016;11:239–49.
14.
go back to reference Chavannes N, Huibers M, Schermer T, Hendriks A, van Weel C, Wouters E, et al. Associations of depressive symptoms with gender, body mass index and dyspnea in primary care COPD patients. Fam Pract. 2005;22(6):604–7.PubMedCrossRef Chavannes N, Huibers M, Schermer T, Hendriks A, van Weel C, Wouters E, et al. Associations of depressive symptoms with gender, body mass index and dyspnea in primary care COPD patients. Fam Pract. 2005;22(6):604–7.PubMedCrossRef
15.
go back to reference Janssen DJ, Spruit MA, Leue C, Gijsen C, Hameleers H, Schols JM, et al. Symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation. Chronic Respir Disease. 2010;7(3):147–57.CrossRef Janssen DJ, Spruit MA, Leue C, Gijsen C, Hameleers H, Schols JM, et al. Symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation. Chronic Respir Disease. 2010;7(3):147–57.CrossRef
16.
go back to reference Al-shair K, Dockry R, Mallia-Milanes B, Kolsum U, Singh D, Vestbo J. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. Respir Med. 2009;103(10):1572–9.PubMedCrossRef Al-shair K, Dockry R, Mallia-Milanes B, Kolsum U, Singh D, Vestbo J. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. Respir Med. 2009;103(10):1572–9.PubMedCrossRef
17.
go back to reference Di Marco F, Verga M, Reggente M, Maria Casanova F, Santus P, Blasi F, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med. 2006;100(10):1767–74.PubMedCrossRef Di Marco F, Verga M, Reggente M, Maria Casanova F, Santus P, Blasi F, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med. 2006;100(10):1767–74.PubMedCrossRef
18.
go back to reference Yohannes AM, Roomi J, Baldwin RC, Connolly MJ. Depression in elderly outpatients with disabling chronic obstructive pulmonary disease. Age Ageing. 1998;27(2):155–60.PubMedCrossRef Yohannes AM, Roomi J, Baldwin RC, Connolly MJ. Depression in elderly outpatients with disabling chronic obstructive pulmonary disease. Age Ageing. 1998;27(2):155–60.PubMedCrossRef
19.
go back to reference Kim HFS, Kunik ME, Molinari VA, Hillman SL, Lalani S, Orengo CA, et al. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics. 2000;41(6):465–71.PubMedCrossRef Kim HFS, Kunik ME, Molinari VA, Hillman SL, Lalani S, Orengo CA, et al. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics. 2000;41(6):465–71.PubMedCrossRef
20.
go back to reference Wall MP. Predictors of functional performance in community-dwelling people with COPD. J Nurs Scholarsh Off Publ Sigma Theta Tau Int Honor Soc Nurs. 2007;39(3):222–8. Wall MP. Predictors of functional performance in community-dwelling people with COPD. J Nurs Scholarsh Off Publ Sigma Theta Tau Int Honor Soc Nurs. 2007;39(3):222–8.
21.
go back to reference Godoy RF, Teixeira PJ, Becker Junior B, Michelli M, Godoy DV. Long-term repercussions of a pulmonary rehabilitation program on the indices of anxiety, depression, quality of life and physical performance in patients with COPD. Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2009;35(2):129–36.CrossRef Godoy RF, Teixeira PJ, Becker Junior B, Michelli M, Godoy DV. Long-term repercussions of a pulmonary rehabilitation program on the indices of anxiety, depression, quality of life and physical performance in patients with COPD. Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2009;35(2):129–36.CrossRef
22.
go back to reference Trappenburg JC, Troosters T, Spruit MA, Vandebrouck N, Decramer M, Gosselink R. Psychosocial conditions do not affect short-term outcome of multidisciplinary rehabilitation in chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2005;86(9):1788–92.PubMedCrossRef Trappenburg JC, Troosters T, Spruit MA, Vandebrouck N, Decramer M, Gosselink R. Psychosocial conditions do not affect short-term outcome of multidisciplinary rehabilitation in chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2005;86(9):1788–92.PubMedCrossRef
23.
go back to reference Weaver TE, Richmond TS, Narsavage GL. An explanatory model of functional status in chronic obstructive pulmonary disease. Nurs Res. 1997;46(1):26–31.PubMedCrossRef Weaver TE, Richmond TS, Narsavage GL. An explanatory model of functional status in chronic obstructive pulmonary disease. Nurs Res. 1997;46(1):26–31.PubMedCrossRef
24.
go back to reference Yeh ML, Chen HH, Liao YC, Liao WY. Testing the functional status model in patients with chronic obstructive pulmonary disease. J Adv Nurs. 2004;48(4):342–50.PubMedCrossRef Yeh ML, Chen HH, Liao YC, Liao WY. Testing the functional status model in patients with chronic obstructive pulmonary disease. J Adv Nurs. 2004;48(4):342–50.PubMedCrossRef
25.
go back to reference Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PMA, Pinto-Plata V, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010;104(6):849–57.PubMedCrossRef Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PMA, Pinto-Plata V, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010;104(6):849–57.PubMedCrossRef
26.
go back to reference Jeong M, Kang HK, Song P, Park HK, Jung H, Lee S-S, et al. Hand grip strength in patients with chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Disease. 2017;12:2385–90.CrossRef Jeong M, Kang HK, Song P, Park HK, Jung H, Lee S-S, et al. Hand grip strength in patients with chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Disease. 2017;12:2385–90.CrossRef
27.
go back to reference Cleutjens FAHM, Spruit MA, Ponds RWHM, Vanfleteren LEGW, Franssen FME, Gijsen C, et al. Cognitive impairment and clinical characteristics in patients with chronic obstructive pulmonary disease. Chronic Respir Disease. 2018;15(2):91–102.CrossRef Cleutjens FAHM, Spruit MA, Ponds RWHM, Vanfleteren LEGW, Franssen FME, Gijsen C, et al. Cognitive impairment and clinical characteristics in patients with chronic obstructive pulmonary disease. Chronic Respir Disease. 2018;15(2):91–102.CrossRef
28.
go back to reference Pierobon A, Ranzini L, Torlaschi V, Sini Bottelli E, Giardini A, Bruschi C, et al. Screening for neuropsychological impairment in COPD patients undergoing rehabilitation. PLoS ONE. 2018;13(8):e0199736.PubMedPubMedCentralCrossRef Pierobon A, Ranzini L, Torlaschi V, Sini Bottelli E, Giardini A, Bruschi C, et al. Screening for neuropsychological impairment in COPD patients undergoing rehabilitation. PLoS ONE. 2018;13(8):e0199736.PubMedPubMedCentralCrossRef
29.
go back to reference Engelen MP, Wouters EF, Deutz NE, Menheere PP, Schols AM. Factors contributing to alterations in skeletal muscle and plasma amino acid profiles in patients with chronic obstructive pulmonary disease. Am J Clin Nutr. 2000;72(6):1480–7.PubMedCrossRef Engelen MP, Wouters EF, Deutz NE, Menheere PP, Schols AM. Factors contributing to alterations in skeletal muscle and plasma amino acid profiles in patients with chronic obstructive pulmonary disease. Am J Clin Nutr. 2000;72(6):1480–7.PubMedCrossRef
30.
go back to reference Engelen MPKJ, Deutz NEP, Wouters EFM, Schols AMWJ. Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(4):1488–92.PubMedCrossRef Engelen MPKJ, Deutz NEP, Wouters EFM, Schols AMWJ. Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(4):1488–92.PubMedCrossRef
31.
go back to reference Engelen M, Jonker R, Thaden JJ, Ten Have GAM, Jeon MS, Dasarathy S, et al. Comprehensive metabolic flux analysis to explain skeletal muscle weakness in COPD. Clin Nutr. 2020;39(10):3056–65.PubMedPubMedCentralCrossRef Engelen M, Jonker R, Thaden JJ, Ten Have GAM, Jeon MS, Dasarathy S, et al. Comprehensive metabolic flux analysis to explain skeletal muscle weakness in COPD. Clin Nutr. 2020;39(10):3056–65.PubMedPubMedCentralCrossRef
32.
go back to reference Engelen MPKJ, Wouters EFM, Deutz NEP, Does JD, Schols AMWJ. Effects of exercise on amino acid metabolism in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(4):859–64.PubMedCrossRef Engelen MPKJ, Wouters EFM, Deutz NEP, Does JD, Schols AMWJ. Effects of exercise on amino acid metabolism in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(4):859–64.PubMedCrossRef
33.
go back to reference Jonker R, Deutz NE, Erbland ML, Anderson PJ, Engelen MP. Alterations in whole-body arginine metabolism in chronic obstructive pulmonary disease. Am J Clin Nutr. 2016;103(6):1458–64.PubMedPubMedCentralCrossRef Jonker R, Deutz NE, Erbland ML, Anderson PJ, Engelen MP. Alterations in whole-body arginine metabolism in chronic obstructive pulmonary disease. Am J Clin Nutr. 2016;103(6):1458–64.PubMedPubMedCentralCrossRef
34.
go back to reference Pouw EM, Schols AMWJ, Deutz NEP, Wouters EFM. Plasma and muscle amino acid levels in relation to resting energy expenditure and inflammation in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(3):797–801.PubMedCrossRef Pouw EM, Schols AMWJ, Deutz NEP, Wouters EFM. Plasma and muscle amino acid levels in relation to resting energy expenditure and inflammation in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(3):797–801.PubMedCrossRef
35.
go back to reference DeMyer MK, Shea PA, Hendrie HC, Yoshimura NN. Plasma tryptophan and five other amino acids in depressed and normal subjects. Arch Gen Psychiatry. 1981;38(6):642–6.PubMedCrossRef DeMyer MK, Shea PA, Hendrie HC, Yoshimura NN. Plasma tryptophan and five other amino acids in depressed and normal subjects. Arch Gen Psychiatry. 1981;38(6):642–6.PubMedCrossRef
36.
go back to reference Fernstrom JD. Large neutral amino acids: dietary effects on brain neurochemistry and function. Amino Acids. 2013;45(3):419–30.PubMedCrossRef Fernstrom JD. Large neutral amino acids: dietary effects on brain neurochemistry and function. Amino Acids. 2013;45(3):419–30.PubMedCrossRef
37.
38.
go back to reference Ali-Sisto T, Tolmunen T, Viinamäki H, Mäntyselkä P, Valkonen-Korhonen M, Koivumaa-Honkanen H, et al. Global arginine bioavailability ratio is decreased in patients with major depressive disorder. J Affect Disord. 2018;229:145–51.PubMedCrossRef Ali-Sisto T, Tolmunen T, Viinamäki H, Mäntyselkä P, Valkonen-Korhonen M, Koivumaa-Honkanen H, et al. Global arginine bioavailability ratio is decreased in patients with major depressive disorder. J Affect Disord. 2018;229:145–51.PubMedCrossRef
39.
go back to reference Hess S, Baker G, Gyenes G, Tsuyuki R, Newman S, Le Melledo J-M. Decreased serum l-arginine and l-citrulline levels in major depression. Psychopharmacology. 2017;234(21):3241–7.PubMedCrossRef Hess S, Baker G, Gyenes G, Tsuyuki R, Newman S, Le Melledo J-M. Decreased serum l-arginine and l-citrulline levels in major depression. Psychopharmacology. 2017;234(21):3241–7.PubMedCrossRef
40.
go back to reference Stern AF. The hospital anxiety and depression scale. Occup Med. 2014;64(5):393–4.CrossRef Stern AF. The hospital anxiety and depression scale. Occup Med. 2014;64(5):393–4.CrossRef
41.
go back to reference Nguyen HQ, Fan VS, Herting J, Lee J, Fu M, Chen Z, et al. Patients with COPD with higher levels of anxiety are more physically active. Chest. 2013;144(1):145–51.PubMedPubMedCentralCrossRef Nguyen HQ, Fan VS, Herting J, Lee J, Fu M, Chen Z, et al. Patients with COPD with higher levels of anxiety are more physically active. Chest. 2013;144(1):145–51.PubMedPubMedCentralCrossRef
42.
go back to reference Xiao T, Qiu H, Chen Y, Zhou X, Wu K, Ruan X, et al. Prevalence of anxiety and depression symptoms and their associated factors in mild COPD patients from community settings, Shanghai, China: a cross-sectional study. BMC Psychiatry. 2018;18(1):89.PubMedPubMedCentralCrossRef Xiao T, Qiu H, Chen Y, Zhou X, Wu K, Ruan X, et al. Prevalence of anxiety and depression symptoms and their associated factors in mild COPD patients from community settings, Shanghai, China: a cross-sectional study. BMC Psychiatry. 2018;18(1):89.PubMedPubMedCentralCrossRef
43.
go back to reference Löfberg E, Gutierrez A, Wernerman J, Anderstam B, Mitch WE, Price SR, et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur J Clin Investig. 2002;32(5):345–53.CrossRef Löfberg E, Gutierrez A, Wernerman J, Anderstam B, Mitch WE, Price SR, et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur J Clin Investig. 2002;32(5):345–53.CrossRef
44.
go back to reference Park JK, Deutz NEP, Cruthirds CL, Kirschner SK, Park H, Madigan ML, et al. Risk factors for postural and functional balance impairment in patients with chronic obstructive pulmonary disease. J Clin Med. 2020;9(2):609.PubMedCentralCrossRef Park JK, Deutz NEP, Cruthirds CL, Kirschner SK, Park H, Madigan ML, et al. Risk factors for postural and functional balance impairment in patients with chronic obstructive pulmonary disease. J Clin Med. 2020;9(2):609.PubMedCentralCrossRef
45.
go back to reference Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46(2):153–62.PubMedCrossRef Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46(2):153–62.PubMedCrossRef
46.
go back to reference Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline LN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–54.PubMedCrossRef Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline LN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–54.PubMedCrossRef
47.
go back to reference Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.PubMedCrossRef Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.PubMedCrossRef
48.
go back to reference McNair DM, Lorr M, Droppleman LF. Revised manual for the profile of mood states. San Diego: Educational and Industrial Testing Services; 2003. McNair DM, Lorr M, Droppleman LF. Revised manual for the profile of mood states. San Diego: Educational and Industrial Testing Services; 2003.
49.
go back to reference Jones PW, Quirk FH, Baveystock CM. The St. George’s Respiratory Questionnaire. Respir Med. 1991;85:25–31.PubMedCrossRef Jones PW, Quirk FH, Baveystock CM. The St. George’s Respiratory Questionnaire. Respir Med. 1991;85:25–31.PubMedCrossRef
50.
go back to reference Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD J Chronic Obstr Pulm Disease. 2005;2(1):75–9.CrossRef Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD J Chronic Obstr Pulm Disease. 2005;2(1):75–9.CrossRef
51.
go back to reference VanItallie TB, Yang MU, Heymsfield SB, Funk RC, Boileau RA. Height-normalized indices of the body’s fat-free mass and fat mass: potentially useful indicators of nutritional status. Am J Clin Nutr. 1990;52(6):953–9.PubMedCrossRef VanItallie TB, Yang MU, Heymsfield SB, Funk RC, Boileau RA. Height-normalized indices of the body’s fat-free mass and fat mass: potentially useful indicators of nutritional status. Am J Clin Nutr. 1990;52(6):953–9.PubMedCrossRef
52.
go back to reference Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179–87.PubMedCrossRef Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179–87.PubMedCrossRef
53.
go back to reference Bohannon RW, Magasi SR, Bubela DJ, Wang Y-C, Gershon RC. Grip and knee extension muscle strength reflect a common construct among adults. Muscle Nerve. 2012;46(4):555–8.PubMedPubMedCentralCrossRef Bohannon RW, Magasi SR, Bubela DJ, Wang Y-C, Gershon RC. Grip and knee extension muscle strength reflect a common construct among adults. Muscle Nerve. 2012;46(4):555–8.PubMedPubMedCentralCrossRef
54.
go back to reference Saey D, Debigaré R, LeBlanc P, Mador MJ, Côté CH, Jobin J, et al. Contractile leg fatigue after cycle exercise. Am J Respir Crit Care Med. 2003;168(4):425–30.PubMedCrossRef Saey D, Debigaré R, LeBlanc P, Mador MJ, Côté CH, Jobin J, et al. Contractile leg fatigue after cycle exercise. Am J Respir Crit Care Med. 2003;168(4):425–30.PubMedCrossRef
55.
go back to reference ATS. ATS statement: guidelines for the 6-min walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.CrossRef ATS. ATS statement: guidelines for the 6-min walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.CrossRef
56.
go back to reference Sánchez-Cubillo I, Periáñez JA, Adrover-Roig D, Rodríguez-Sánchez JM, Ríos-Lago M, Tirapu J, et al. Construct validity of the trail making test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc JINS. 2009;15(3):438–50.PubMedCrossRef Sánchez-Cubillo I, Periáñez JA, Adrover-Roig D, Rodríguez-Sánchez JM, Ríos-Lago M, Tirapu J, et al. Construct validity of the trail making test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc JINS. 2009;15(3):438–50.PubMedCrossRef
57.
go back to reference Lamers MJ, Roelofs A, Rabeling-Keus IM. Selective attention and response set in the Stroop task. Mem Cognit. 2010;38(7):893–904.PubMedCrossRef Lamers MJ, Roelofs A, Rabeling-Keus IM. Selective attention and response set in the Stroop task. Mem Cognit. 2010;38(7):893–904.PubMedCrossRef
58.
go back to reference Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643–62.CrossRef Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643–62.CrossRef
59.
go back to reference Valentijn SAM, Van Boxtel MPJ, Van Hooren SAH, Bosma H, Beckers HJM, Ponds RWHM, et al. Change in sensory functioning predicts change in cognitive functioning: results from a 6-year follow-up in the Maastricht Aging Study. J Am Geriatr Soc. 2005;53(3):374–80.PubMedCrossRef Valentijn SAM, Van Boxtel MPJ, Van Hooren SAH, Bosma H, Beckers HJM, Ponds RWHM, et al. Change in sensory functioning predicts change in cognitive functioning: results from a 6-year follow-up in the Maastricht Aging Study. J Am Geriatr Soc. 2005;53(3):374–80.PubMedCrossRef
60.
go back to reference Deutz NEP, Thaden JJ, ten Have GAM, Walker DK, Engelen MPKJ. Metabolic phenotyping using kinetic measurements in young and older healthy adults. Metabolism. 2018;78:167–78.PubMedCrossRef Deutz NEP, Thaden JJ, ten Have GAM, Walker DK, Engelen MPKJ. Metabolic phenotyping using kinetic measurements in young and older healthy adults. Metabolism. 2018;78:167–78.PubMedCrossRef
61.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.PubMedCrossRef
62.
go back to reference Engelen MPKJ, Ten Have GAM, Thaden JJ, Deutz NEP. New advances in stable tracer methods to assess whole-body protein and amino acid metabolism. Curr Opin Clin Nutr Metab Care. 2019;22(5):337–46.PubMedCrossRef Engelen MPKJ, Ten Have GAM, Thaden JJ, Deutz NEP. New advances in stable tracer methods to assess whole-body protein and amino acid metabolism. Curr Opin Clin Nutr Metab Care. 2019;22(5):337–46.PubMedCrossRef
63.
go back to reference Mason A, Engelen M, Ivanov I, Toffolo GM, Deutz NEP. A four-compartment compartmental model to assess net whole body protein breakdown using a pulse of phenylalanine and tyrosine stable isotopes in humans. Am J Physiol Endocrinol Metab. 2017;313(1):E63–74.PubMedPubMedCentralCrossRef Mason A, Engelen M, Ivanov I, Toffolo GM, Deutz NEP. A four-compartment compartmental model to assess net whole body protein breakdown using a pulse of phenylalanine and tyrosine stable isotopes in humans. Am J Physiol Endocrinol Metab. 2017;313(1):E63–74.PubMedPubMedCentralCrossRef
64.
go back to reference Wolfe R, Chinkes D. Isotope tracers in metabolic research: principles and practice of kinetic analysis. New York: Wiley; 2005. p. 274. Wolfe R, Chinkes D. Isotope tracers in metabolic research: principles and practice of kinetic analysis. New York: Wiley; 2005. p. 274.
65.
go back to reference Mi E, Mi E, Ewing G, Mahadeva R, Gardener AC, Holt Butcher H, et al. Associations between the psychological health of patients and carers in advanced COPD. Int J Chronic Obstr Pulm Disease. 2017;12:2813–21.CrossRef Mi E, Mi E, Ewing G, Mahadeva R, Gardener AC, Holt Butcher H, et al. Associations between the psychological health of patients and carers in advanced COPD. Int J Chronic Obstr Pulm Disease. 2017;12:2813–21.CrossRef
66.
go back to reference Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019;49(12):1958–70.PubMedPubMedCentralCrossRef Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019;49(12):1958–70.PubMedPubMedCentralCrossRef
67.
go back to reference Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease. Circulation. 2003;107(3):499–511.PubMedCrossRef Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease. Circulation. 2003;107(3):499–511.PubMedCrossRef
68.
go back to reference Albrecht JS, Park Y, Hur P, Huang TY, Harris I, Netzer G, et al. Adherence to maintenance medications among older adults with chronic obstructive pulmonary disease: the role of depression. Ann Am Thorac Soc. 2016;13(9):1497–504.PubMedPubMedCentralCrossRef Albrecht JS, Park Y, Hur P, Huang TY, Harris I, Netzer G, et al. Adherence to maintenance medications among older adults with chronic obstructive pulmonary disease: the role of depression. Ann Am Thorac Soc. 2016;13(9):1497–504.PubMedPubMedCentralCrossRef
69.
70.
go back to reference Yohannes AM, Connolly MJ, Baldwin RC. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2001;16(5):451–4.PubMedCrossRef Yohannes AM, Connolly MJ, Baldwin RC. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2001;16(5):451–4.PubMedCrossRef
71.
go back to reference Fan VS, Ramsey SD, Giardino ND, Make BJ, Emery CF, Diaz PT, et al. Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med. 2007;167(21):2345–53.PubMedCrossRef Fan VS, Ramsey SD, Giardino ND, Make BJ, Emery CF, Diaz PT, et al. Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med. 2007;167(21):2345–53.PubMedCrossRef
72.
go back to reference von Leupoldt A, Taube K, Lehmann K, Fritzsche A, Magnussen H. The impact of anxiety and depression on outcomes of pulmonary rehabilitation in COPD. Eur Respir J. 2011;38(Suppl 55):p3638. von Leupoldt A, Taube K, Lehmann K, Fritzsche A, Magnussen H. The impact of anxiety and depression on outcomes of pulmonary rehabilitation in COPD. Eur Respir J. 2011;38(Suppl 55):p3638.
73.
go back to reference Lucca A, Lucini V, Catalano M, Alfano M, Smeraldi E. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor. Neuropsychobiology. 1994;29(3):108–11.PubMedCrossRef Lucca A, Lucini V, Catalano M, Alfano M, Smeraldi E. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor. Neuropsychobiology. 1994;29(3):108–11.PubMedCrossRef
74.
go back to reference Møller SE, Bech P, Bjerrum H, Bøjholm S, Butler B, Folker H, et al. Plasma ratio tryptophan/neutral amino acids in relation to clinical response to paroxetine and clomipramine in patients with major depression. J Affect Disord. 1990;18(1):59–66.PubMedCrossRef Møller SE, Bech P, Bjerrum H, Bøjholm S, Butler B, Folker H, et al. Plasma ratio tryptophan/neutral amino acids in relation to clinical response to paroxetine and clomipramine in patients with major depression. J Affect Disord. 1990;18(1):59–66.PubMedCrossRef
75.
go back to reference Møller SE, de Beurs P, Timmerman L, Tan BK, Leijnse-Ybema HJ, Cohen Stuart MH, et al. Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. Psychopharmacology. 1986;88(1):96–100.PubMedCrossRef Møller SE, de Beurs P, Timmerman L, Tan BK, Leijnse-Ybema HJ, Cohen Stuart MH, et al. Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. Psychopharmacology. 1986;88(1):96–100.PubMedCrossRef
76.
go back to reference Carlsson A, Lindqvist M. Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino-acids in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1978;303(2):157–64.PubMedCrossRef Carlsson A, Lindqvist M. Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino-acids in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1978;303(2):157–64.PubMedCrossRef
77.
go back to reference Pirina P, Zinellu E, Paliogiannis P, Fois AG, Marras V, Sotgia S, et al. Circulating serotonin levels in COPD patients: a pilot study. BMC Pulm Med. 2018;18(1):167.PubMedPubMedCentralCrossRef Pirina P, Zinellu E, Paliogiannis P, Fois AG, Marras V, Sotgia S, et al. Circulating serotonin levels in COPD patients: a pilot study. BMC Pulm Med. 2018;18(1):167.PubMedPubMedCentralCrossRef
78.
go back to reference Meier MA, Ottiger M, Vögeli A, Steuer C, Bernasconi L, Thomann R, et al. Activation of the serotonin pathway is associated with poor outcome in COPD exacerbation: results of a long-term cohort study. Lung. 2017;195(3):303–11.PubMedCrossRef Meier MA, Ottiger M, Vögeli A, Steuer C, Bernasconi L, Thomann R, et al. Activation of the serotonin pathway is associated with poor outcome in COPD exacerbation: results of a long-term cohort study. Lung. 2017;195(3):303–11.PubMedCrossRef
79.
go back to reference Lau WKW, Chan-Yeung MMW, Yip BHK, Cheung AHK, Ip MSM, Mak JCW, et al. The role of circulating serotonin in the development of chronic obstructive pulmonary disease. PLoS ONE. 2012;7(2):e31617.PubMedPubMedCentralCrossRef Lau WKW, Chan-Yeung MMW, Yip BHK, Cheung AHK, Ip MSM, Mak JCW, et al. The role of circulating serotonin in the development of chronic obstructive pulmonary disease. PLoS ONE. 2012;7(2):e31617.PubMedPubMedCentralCrossRef
80.
go back to reference Yoneda T, Yoshikawa M, Fu A, Tsukaguchi K, Okamoto Y, Takenaka H. Plasma levels of amino acids and hypermetabolism in patients with chronic obstructive pulmonary disease. Nutrition. 2001;17(2):95–9.PubMedCrossRef Yoneda T, Yoshikawa M, Fu A, Tsukaguchi K, Okamoto Y, Takenaka H. Plasma levels of amino acids and hypermetabolism in patients with chronic obstructive pulmonary disease. Nutrition. 2001;17(2):95–9.PubMedCrossRef
81.
go back to reference Baranyi A, Amouzadeh-Ghadikolai O, von Lewinski D, Rothenhäusler H-B, Theokas S, Robier C, et al. Branched-chain amino acids as new biomarkers of major depression—a novel neurobiology of mood disorder. PLoS ONE. 2016;11(8):e0160542-e.CrossRef Baranyi A, Amouzadeh-Ghadikolai O, von Lewinski D, Rothenhäusler H-B, Theokas S, Robier C, et al. Branched-chain amino acids as new biomarkers of major depression—a novel neurobiology of mood disorder. PLoS ONE. 2016;11(8):e0160542-e.CrossRef
82.
go back to reference Koochakpoor G, Salari-Moghaddam A, Keshteli AH, Afshar H, Esmaillzadeh A, Adibi P. Dietary intake of branched-chain amino acids in relation to depression, anxiety and psychological distress. Nutr J. 2021;20(1):11.PubMedPubMedCentralCrossRef Koochakpoor G, Salari-Moghaddam A, Keshteli AH, Afshar H, Esmaillzadeh A, Adibi P. Dietary intake of branched-chain amino acids in relation to depression, anxiety and psychological distress. Nutr J. 2021;20(1):11.PubMedPubMedCentralCrossRef
83.
go back to reference van de Bool C, Rutten EPA, van Helvoort A, Franssen FME, Wouters EFM, Schols AMWJ. A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J Cachexia Sarcopenia Muscle. 2017;8(5):748–58.PubMedPubMedCentralCrossRef van de Bool C, Rutten EPA, van Helvoort A, Franssen FME, Wouters EFM, Schols AMWJ. A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J Cachexia Sarcopenia Muscle. 2017;8(5):748–58.PubMedPubMedCentralCrossRef
84.
go back to reference Nasrallah P, Haidar EA, Stephan JS, El Hayek L, Karnib N, Khalifeh M, et al. Branched-chain amino acids mediate resilience to chronic social defeat stress by activating BDNF/TRKB signaling. Neurobiol Stress. 2019;11:100170.PubMedPubMedCentralCrossRef Nasrallah P, Haidar EA, Stephan JS, El Hayek L, Karnib N, Khalifeh M, et al. Branched-chain amino acids mediate resilience to chronic social defeat stress by activating BDNF/TRKB signaling. Neurobiol Stress. 2019;11:100170.PubMedPubMedCentralCrossRef
85.
go back to reference Wrann Christiane D, White James P, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 Pathway. Cell Metab. 2013;18(5):649–59.PubMedPubMedCentralCrossRef Wrann Christiane D, White James P, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 Pathway. Cell Metab. 2013;18(5):649–59.PubMedPubMedCentralCrossRef
86.
go back to reference Lee B-H, Kim Y-K. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 2010;7(4):231–5.PubMedPubMedCentralCrossRef Lee B-H, Kim Y-K. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 2010;7(4):231–5.PubMedPubMedCentralCrossRef
88.
go back to reference Papp C, Pak K, Erdei T, Juhasz B, Seres I, Szentpéteri A, et al. Alteration of the irisin-brain-derived neurotrophic factor axis contributes to disturbance of mood in COPD patients. Int J Chronic Obstr Pulm Disease. 2017;12:2023–33.CrossRef Papp C, Pak K, Erdei T, Juhasz B, Seres I, Szentpéteri A, et al. Alteration of the irisin-brain-derived neurotrophic factor axis contributes to disturbance of mood in COPD patients. Int J Chronic Obstr Pulm Disease. 2017;12:2023–33.CrossRef
89.
90.
go back to reference Wohleb ES, Gerhard D, Thomas A, Duman RS. Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine. Curr Neuropharmacol. 2017;15(1):11–20.PubMedPubMedCentralCrossRef Wohleb ES, Gerhard D, Thomas A, Duman RS. Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine. Curr Neuropharmacol. 2017;15(1):11–20.PubMedPubMedCentralCrossRef
91.
92.
go back to reference Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121–9.PubMedPubMedCentralCrossRef Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121–9.PubMedPubMedCentralCrossRef
93.
go back to reference Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–64.PubMedCrossRef Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–64.PubMedCrossRef
94.
go back to reference Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression—first FDA-approved antidepressant in a new class. N Engl J Med. 2019;381(1):1–4.PubMedCrossRef Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression—first FDA-approved antidepressant in a new class. N Engl J Med. 2019;381(1):1–4.PubMedCrossRef
95.
go back to reference Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler H-B, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):e0143397.PubMedPubMedCentralCrossRef Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler H-B, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):e0143397.PubMedPubMedCentralCrossRef
96.
go back to reference Jesse CR, Bortolatto CF, Savegnago L, Rocha JBT, Nogueira CW. Involvement of l-arginine–nitric oxide–cyclic guanosine monophosphate pathway in the antidepressant-like effect of tramadol in the rat forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1838–43.PubMedCrossRef Jesse CR, Bortolatto CF, Savegnago L, Rocha JBT, Nogueira CW. Involvement of l-arginine–nitric oxide–cyclic guanosine monophosphate pathway in the antidepressant-like effect of tramadol in the rat forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1838–43.PubMedCrossRef
97.
go back to reference Lu Y-R, Zhang Y, Rao Y-B, Chen X, Lou H-F, Zhang Y, et al. The changes in, and relationship between, plasma nitric oxide and corticotropin-releasing hormone in patients with major depressive disorder. Clin Exp Pharmacol Physiol. 2018;45(1):10–5.PubMedCrossRef Lu Y-R, Zhang Y, Rao Y-B, Chen X, Lou H-F, Zhang Y, et al. The changes in, and relationship between, plasma nitric oxide and corticotropin-releasing hormone in patients with major depressive disorder. Clin Exp Pharmacol Physiol. 2018;45(1):10–5.PubMedCrossRef
98.
go back to reference Ozden A, Angelos H, Feyza A, Elizabeth W, John P. Altered plasma levels of arginine metabolites in depression. J Psychiatr Res. 2020;120:21–8.PubMedCrossRef Ozden A, Angelos H, Feyza A, Elizabeth W, John P. Altered plasma levels of arginine metabolites in depression. J Psychiatr Res. 2020;120:21–8.PubMedCrossRef
99.
101.
go back to reference Otero Losada ME, Rubio MC. Acute effects of S-adenosyl-l-methionine on catecholaminergic central function. Eur J Pharmacol. 1989;163(2):353–6.CrossRef Otero Losada ME, Rubio MC. Acute effects of S-adenosyl-l-methionine on catecholaminergic central function. Eur J Pharmacol. 1989;163(2):353–6.CrossRef
102.
go back to reference Otero-Losada ME, Rubio MC. Acute changes in 5-HT metabolism after S-adenosyl-l-methionine administration. Gen Pharmacol Vasc Syst. 1989;20(4):403–6.CrossRef Otero-Losada ME, Rubio MC. Acute changes in 5-HT metabolism after S-adenosyl-l-methionine administration. Gen Pharmacol Vasc Syst. 1989;20(4):403–6.CrossRef
103.
go back to reference Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev J Clin Ther. 2008;13(3):216–26. Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev J Clin Ther. 2008;13(3):216–26.
104.
go back to reference Sumi-Ichinose C, Urano F, Kuroda R, Ohye T, Kojima M, Tazawa M, et al. Catecholamines and serotonin are differently regulated by tetrahydrobiopterin: a study from 6-pyruvoyltetrahydropterin synthase knockout mice*. J Biol Chem. 2001;276(44):41150–60.PubMedCrossRef Sumi-Ichinose C, Urano F, Kuroda R, Ohye T, Kojima M, Tazawa M, et al. Catecholamines and serotonin are differently regulated by tetrahydrobiopterin: a study from 6-pyruvoyltetrahydropterin synthase knockout mice*. J Biol Chem. 2001;276(44):41150–60.PubMedCrossRef
105.
go back to reference Cuomo A, Beccarini Crescenzi B, Bolognesi S, Goracci A, Koukouna D, Rossi R, et al. S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review. Ann Gen Psychiatry. 2020;19(1):50.PubMedPubMedCentralCrossRef Cuomo A, Beccarini Crescenzi B, Bolognesi S, Goracci A, Koukouna D, Rossi R, et al. S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review. Ann Gen Psychiatry. 2020;19(1):50.PubMedPubMedCentralCrossRef
106.
go back to reference Turner P, Kantaria R, Young AH. A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective. J Psychopharmacol. 2014;28(2):85–98.PubMedCrossRef Turner P, Kantaria R, Young AH. A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective. J Psychopharmacol. 2014;28(2):85–98.PubMedCrossRef
Metadata
Title
Disturbances in branched-chain amino acid profile and poor daily functioning in mildly depressed chronic obstructive pulmonary disease patients
Authors
Marisa R. Pinson
Nicolaas E. P. Deutz
Rajesh Harrykissoon
Anthony J. Zachria
Mariëlle P. K. J. Engelen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01719-9

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.